These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Mueller BA; Scarim SK; Macias WL Am J Kidney Dis; 1993 Feb; 21(2):172-9. PubMed ID: 8430678 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103 [TBL] [Abstract][Full Text] [Related]
4. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Keller E; Fecht H; Böhler J; Schollmeyer P Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062 [TBL] [Abstract][Full Text] [Related]
5. Imipenem/cilastin dosage during acute renal failure and hemofiltration. Dehne MG; Kroh UF Intensive Care Med; 1995 Oct; 21(10):863. PubMed ID: 8557879 [No Abstract] [Full Text] [Related]
6. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration. Przechera M; Bengel D; Risler T Contrib Nephrol; 1991; 93():131-4. PubMed ID: 1802563 [No Abstract] [Full Text] [Related]
7. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Vos MC; Vincent HH; Yzerman EP Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259 [TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Fish DN; Teitelbaum I; Abraham E Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542 [TBL] [Abstract][Full Text] [Related]
10. Using imipenem and cilastatin during continuous renal replacement therapy. Cotton A; Franklin BD; Brett S; Holmes A Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371 [TBL] [Abstract][Full Text] [Related]
13. [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. Bégué P; Quinet B; Baron S; Challier P; Fontaine JL; Lasfargues G Pathol Biol (Paris); 1989 May; 37(5):485-90. PubMed ID: 2674874 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939 [TBL] [Abstract][Full Text] [Related]